SCHEMBL6853146

SCHEMBL6853146

CCOCCC(OCC)OC(=O)N1C(=O)C(O[Si](CC)(CC)CC)C1c1cccs1

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.34
ADORA3 P0DMS8 1/20 0.34
MEN1 O00255 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
PKM P14618 2/20 0.34
NPC1 O15118 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ADORA2B P29275 5/20 0.33
KDM4E B2RXH2 4/20 0.33
ALDH1A1 P00352 3/20 0.33
POLB P06746 3/20 0.33
HTT P42858 1/20 0.33
TSHR P16473 2/20 0.32
HSD17B10 Q99714 2/20 0.32
HPGD P15428 1/20 0.32
BRD4 O60885 1/20 0.32
LMNA P02545 1/20 0.32
CASP1 P29466 1/20 0.32
CASP7 P55210 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8709401 0.86 ELANE (0.38) NPSR1KDM4EPOLBHTT
SCHEMBL6853148 0.84 KMT2A (0.37) KMT2AADORA3MEN1NPSR1PKM
SCHEMBL6860255 0.83 ADORA2B (0.36) NPSR1SMN1; SMN2ADORA2BKDM4EALDH1A1
SCHEMBL6861172 0.82 POLB (0.42) KMT2AMEN1NPSR1PKMSMN1; SMN2
SCHEMBL6861174 0.82 POLB (0.42) KMT2AMEN1NPSR1PKMSMN1; SMN2
SCHEMBL6861179 0.82 POLB (0.42) KMT2AMEN1NPSR1PKMSMN1; SMN2
SCHEMBL6858753 0.82 PKM (0.46) KMT2AADORA3MEN1NPSR1PKM
SCHEMBL6858758 0.82 PKM (0.46) KMT2AADORA3MEN1NPSR1PKM
SCHEMBL6858762 0.82 PKM (0.46) KMT2AADORA3MEN1NPSR1PKM
SCHEMBL6861585 0.78 ADORA2B (0.46) KMT2AADORA3MEN1NPSR1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6794523-B2 ANTICANCER AGENTS, ANTITUMOR AGENTS; LEUKEMIA FLORIDA STATE UNIVERSITY 2004-09-21 US disclosed
US-20030065200-A1 Anticancer agents, antitumor agents; leukemia FLORIDA STATE UNIVERSITY 2003-04-03 US disclosed
US-6018073-A Tricyclic taxanes having an alkoxy, alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing them FLORIDA STATE UNIVERSITY (US) 2000-01-25 US disclosed
US-5739362-A ANTILEUKEMIA, ANTITUMOR AGENTS FLORIDA STATE UNIVERSITY (US) 1998-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065200-A1 Anticancer agents, antitumor agents; leukemia MCL1, BCL3, TOP2A KMT2A 1890/4885ADORA3 2525/4885MEN1 2533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.